<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4924">
  <stage>Registered</stage>
  <submitdate>1/10/2014</submitdate>
  <approvaldate>1/10/2014</approvaldate>
  <nctid>NCT02279173</nctid>
  <trial_identification>
    <studytitle>Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP.</studytitle>
    <scientifictitle>A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-005019-96</secondaryid>
    <secondaryid>20101221</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immune Thrombocytopenia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Romiplostim

Experimental: Romiplostim - Romiplostim subcutaneous weekly injection


Treatment: drugs: Romiplostim
Romiplostim subcutaneous weekly injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The percentage of time with a platelet count of = 50 x 10^9/L starting from week 2 in the first 6 months of the treatment period without rescue medication use in the past 4 weeks - The percentage of time with a platelet count of = 50 x 10^9/L starting from week 2 in the first 6 months of the treatment period without rescue medication use in the past 4 weeks</outcome>
      <timepoint>6 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of time with a platelet count of = 50 x 10^9/L starting from week 2 until the end of the treatment period without rescue medication use in the past 4 weeks -  The percentage of time with a platelet count of = 50 x 10^9/L starting from week 2 until the end of the treatment period without rescue medication use in the past 4 weeks</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of time with an increase in platelet count = 20 x10^9/L above baseline starting from week 2 until the end of the treatment period without rescue medication use within the past 4 weeks. - The percentage of time with an increase in platelet count = 20 x10^9/L above baseline starting from week 2 until the end of the treatment period without rescue medication use within the past 4 weeks.</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject incidence of rescue ITP medications used - Subject incidence of rescue ITP medications used</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The incidence of anti-romiplostim neutralizing antibodies and cross-reactive antibodies to thrombopoietin (TPO) at any time during the study - The incidence of anti-romiplostim neutralizing antibodies and cross-reactive antibodies to thrombopoietin (TPO) at any time during the study</outcome>
      <timepoint>38 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The incidence of adverse events, including clinically significant changes in laboratory values - The incidence of adverse events, including clinically significant changes in laboratory values</outcome>
      <timepoint>38 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of primary ITP according to The American Society of Hematology (ASH) Guidelines
        (Neunert et al, 2011) at least 6 months before screening, regardless of splenectomy status

        Age = 1 year and &lt; 18 years of age

        Refractory to prior ITP therapy, relapsed after at prior ITP therapy, or be ineligible for
        other therapies Examples of prior therapy include: corticosteroids, IVIG, anti-D
        immunoglobulin, platelet transfusions.

        Platelet count = 30 x10^9/L or is experiencing uncontrolled bleeding

        Has provided informed consent before any study-specific procedure;

        Adequate hematologic, renal, and liver function during screening Hemoglobin &gt; 10.0 g/dL
        Serum creatinine = 1.5 x the ULN Total serum bilirubin = 1.5 x the ULN AST and ALT = 3.0 x
        the ULN</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of a bone marrow stem cell disorder (Any abnormal bone marrow findings other than
        those typical of ITP must be approved by Amgen before a subject may be enrolled)

        Prior bone marrow transplant or peripheral blood progenitor cell transplant

        Active or prior malignancy except non-melanoma skin cancers within the last 5 years

        History of myelodysplastic syndrome

        History of bleeding diathesis

        History of congenital thrombocytopenia

        History of HepB, HepC or HIV

        History of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia

        History of antiphospholipid antibody syndrome or known positive for lupus anticoagulant

        History of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic
        thrombocytopenic purpura

        History of venous thromboembolism or thrombotic events

        Previous use of romiplostim or previous use of eltrombopag within 4 weeks of enrollment

        Previous use of PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO) or any other
        platelet producing agent

        Rituximab (for any indication) or 6-mercaptopurine within 8 weeks of enrollment, or
        anticipated use at any time during the study

        Splenectomy within 4 weeks of the screening visit

        Alkylating agents within 8 weeks before the screening visit or anticipated use during the
        time of the proposed study

        Vaccinations known to decrease platelet counts within 8 weeks before the screening visit

        Currently enrolled in another investigational device or drug study, or less than 30 days
        since ending investigational study

        Will have investigational procedures while enrolled on study

        Female subject of child bearing potential (defined as having first menses) not willing to
        use, in combination with her partner highly effective methods of birth control during
        treatment and for 1 month after the end of treatment

        Subject is pregnant or breast feeding, or might become pregnant within

        1 month after the end of treatment

        Subject has known hypersensitivity to any recombinant Escherichia coli derived product (eg,
        Infergen®, Neupogen®, somatropin, and Actimmune®)

        Has previously enrolled into this study

        Will not be available for protocol-required study visits or procedures, to the best of the
        subject's and investigator's knowledge

        Any kind of disorder that, may compromise the subject to give written informed consent
        and/or to comply with all required study procedures</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>10/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>204</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>23/09/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Research Site - Randwick</hospital>
    <hospital>Research Site - South Brisbane</hospital>
    <hospital>Research Site - Parkville</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Pará</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava-Poruba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier cedex 05</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Sheva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikvah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo León</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Zabrze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Krasnodar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saratov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Volgograd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>KwaZulu-Natal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Comunidad Valenciana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>St. Gallen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zuerich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Adana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Antalya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 3b single arm, open label, multicenter study describing the percentage of
      time pediatric subjects with ITP have a platelet response while receiving romiplostim,
      defined as a platelet count = 50 x 10^9/L and in the absence of ITP rescue medications in the
      past 4 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02279173</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>